The global market for cardiovascular risk reduction therapies is witnessing substantial and necessary expansion, fundamentally driven by the escalating worldwide burden of cardiovascular diseases (CVDs). As a critical segment of the broader pharmaceutical and medical device industries, this market focuses on pharmacological and interventional strategies aimed at preventing primary and...